Fulgent Genetics Stock Jumps 27% the Day After Q3 Results and Improved Loss Outlook

Fulgent Genetics (Nasdaq: FLGT) shares rose 27.2% on Friday, Nov. 6, 2026, closing at $23.74 from a previous close of $18.66, the session after the company reported third-quarter results. The S&P 500 ETF (SPY) rose 0.31% over the same session, and volume ran about 3.8 times its usual level.

The results were disclosed in an 8-K filed Nov. 5 after the close, with the earnings press release furnished as an exhibit. The company reported third-quarter revenue of $90.4 million, up about 8% from a year earlier, and a GAAP loss of $13.2 million, or $(0.48) per share. The non-GAAP loss was $2.4 million, or $(0.09) per share.

Guidance held, loss outlook improved

Fulgent maintained its full-year 2026 revenue guidance of $330.0 million to $340.0 million. It now expects a full-year non-GAAP loss of approximately $46.0 million to $50.0 million, and said it improved that outlook along with its cash guidance because of disciplined spending across the business.

CFO Paul Kim said the quarter was driven by an improvement in collection rates and that the company had made progress on a billing system issue.

Cash position

At the end of the third quarter, Fulgent had $86.8 million in cash and cash equivalents, $206.0 million in short-term investments and $359.6 million in long-term marketable securities, or $652.3 million in cash and investments together. For full-year 2026 the company expects about $630.0 million in cash and investments, after $64.1 million spent on its stock repurchase program through Sept. 30.